CN1188169C - 抗体用于抗癌接种的用途 - Google Patents

抗体用于抗癌接种的用途 Download PDF

Info

Publication number
CN1188169C
CN1188169C CNB008027641A CN00802764A CN1188169C CN 1188169 C CN1188169 C CN 1188169C CN B008027641 A CNB008027641 A CN B008027641A CN 00802764 A CN00802764 A CN 00802764A CN 1188169 C CN1188169 C CN 1188169C
Authority
CN
China
Prior art keywords
antibodies
antibody
vaccination
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008027641A
Other languages
English (en)
Chinese (zh)
Other versions
CN1344167A (zh
Inventor
H·艾克特
H·罗比尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH filed Critical Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-GmbH
Publication of CN1344167A publication Critical patent/CN1344167A/zh
Application granted granted Critical
Publication of CN1188169C publication Critical patent/CN1188169C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008027641A 1999-01-13 2000-01-12 抗体用于抗癌接种的用途 Expired - Fee Related CN1188169C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH51/99 1999-01-13
CH51/1999 1999-01-13
CH5199 1999-01-13

Publications (2)

Publication Number Publication Date
CN1344167A CN1344167A (zh) 2002-04-10
CN1188169C true CN1188169C (zh) 2005-02-09

Family

ID=4178206

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008027641A Expired - Fee Related CN1188169C (zh) 1999-01-13 2000-01-12 抗体用于抗癌接种的用途

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1230932B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE286745T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50000243D1 (enExample)
DK (2) DK1230932T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2177509T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1230932E (enExample)
SI (2) SI1230932T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2006005367A1 (en) 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
EP1618890B1 (en) * 2004-07-20 2010-10-06 Altropus Gmbh Use of antibodies in a very low dose for the vaccination against cancer
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
EP2217253B1 (en) 2007-12-07 2011-06-29 N.V. Nutricia Bifidobacterium for dust mite allergy
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AU2001261371A1 (en) 2000-05-16 2001-11-26 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same

Also Published As

Publication number Publication date
ATE219687T1 (de) 2002-07-15
US20120003232A1 (en) 2012-01-05
IL144265A (en) 2006-08-20
AU768515B2 (en) 2003-12-18
KR20010101446A (ko) 2001-11-14
ES2177509T3 (es) 2002-12-16
SI1140168T1 (en) 2002-10-31
HRP20010526A2 (en) 2002-08-31
HK1044487A1 (en) 2002-10-25
PL201533B1 (pl) 2009-04-30
EP1140168A1 (de) 2001-10-10
CN1344167A (zh) 2002-04-10
WO2000041722A1 (de) 2000-07-20
TR200102034T2 (tr) 2001-11-21
US20070224202A1 (en) 2007-09-27
EP1230932B1 (de) 2005-01-12
PL364747A1 (en) 2004-12-13
CA2360382A1 (en) 2000-07-20
CA2360382C (en) 2011-05-24
EE05474B1 (et) 2011-10-17
DE50009240D1 (de) 2005-02-17
JP2002534481A (ja) 2002-10-15
SK9642001A3 (en) 2002-03-05
PT1140168E (pt) 2002-11-29
KR100771752B1 (ko) 2007-10-30
NO329917B1 (no) 2011-01-24
HU226150B1 (en) 2008-05-28
DK1230932T3 (da) 2005-04-25
US20100233178A1 (en) 2010-09-16
US8444974B2 (en) 2013-05-21
HUP0200527A2 (en) 2002-06-29
NZ512722A (en) 2003-07-25
DK1140168T3 (da) 2002-09-30
DE50000243D1 (de) 2002-08-01
NO20013093D0 (no) 2001-06-21
ATE286745T1 (de) 2005-01-15
AU2796400A (en) 2000-08-01
JP4774551B2 (ja) 2011-09-14
CZ302801B6 (cs) 2011-11-16
EP1140168B1 (de) 2002-06-26
ES2236375T3 (es) 2005-07-16
SI1230932T1 (en) 2005-06-30
US7691372B2 (en) 2010-04-06
EP1230932A3 (de) 2003-11-26
EE200100366A (et) 2002-10-15
CZ20012581A3 (cs) 2002-01-16
IL144265A0 (en) 2002-05-23
MXPA01007148A (es) 2002-03-27
SK286627B6 (sk) 2009-02-05
IS5998A (is) 2001-07-10
EP1230932A2 (de) 2002-08-14
PT1230932E (pt) 2005-04-29
ID30223A (id) 2001-11-15
HK1044487B (zh) 2005-09-16
NO20013093L (no) 2001-09-10

Similar Documents

Publication Publication Date Title
CN1188169C (zh) 抗体用于抗癌接种的用途
CN100349920C (zh) 神经节苷脂相关的重组抗体及其在制备肿瘤的诊断和治疗的药物中的应用
CN1639194A (zh) 抗癌抗体
CN1291755C (zh) 增强低免疫原性抗原的免疫原性的药物组合物
CN1193353A (zh) 变应原－xcd32融合蛋白
CN1390138A (zh) 抗体作疫苗的新用途
CN1273191C (zh) 用于改变b细胞介导病理的方法和组合物
CN1960744A (zh) 肽IL1β和TNFα以及应用其治疗的方法
CN1522155A (zh) 生产疫苗的方法
CN1313484C (zh) 人b细胞特异性膜分子cd20的12氨基酸模拟表位及其用该模拟表位构建的多肽表位疫苗
CN1634978A (zh) Sars病毒hla－a2限制性表位多肽及其应用
US20040265318A1 (en) Use of antibodies for the vaccination against cancer
HK1070080B (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050209

Termination date: 20130112